

Survey: DS4/21
month: November 2021
Participant-No: 9907016
date of issue: 13.11.21



Referenzinstitut für Bioanalytik



Survey directors
Prof. Dr. C. Knabbe
Prof. Dr. Dr. K.P. Kohse
Prof. Dr. M. Neumaier

Head of RfB
Dr. W. J. Geilenkeuser
Dr. A. Kessler

Krajská nemocnice T. Bati, a.s.
Oddeleni klinické biochemie
a farmakologie
Prim. MUDr. Tomáš Sálek, Ph.D., EuSpLM
Havlickovo nábřeží 600
76275 ZLIN
CZECH REPUBLIC

Participation certificate

We confirm that you have participated in the survey for drug screening.
Your findings and the corresponding ratings were the following:
(* = correct, f = false, ? = missing, # = false positive)

Bonn, 22. November 2021

I. Screening (immunologic)

	Sample A		Sample B	
	findings	rating	findings	rating
- Amphetamine group	-	•	-	•
- Barbiturates	-	•	-	•
- Benzodiazepines	-	•	-	•
- Cannabinoids	-	•	+	•
- Cocain + metabolites	-	•	+	•
- Methadon + metabolites	-	•	+	•
- Opiates	-	•	+	•
- Tricycl. antidepressants	-	•	+	•
- Metamphetamin	-	•	+	•

C. Knabbe *Dr. J. Geilenkeuser* *A. Kessler*

Survey: DS4/21
month: November 2021
Participant-No: 9907016
date of issue: 13.11.21



Referenzinstitut für Bioanalytik



Survey directors
Prof. Dr. C. Knabbe
Prof. Dr. Dr. K.P. Kohse
Prof. Dr. M. Neumaier

Head of RfB
Dr. W. J. Geilenkeuser
Dr. A. Kessler

Krajská nemocnice T. Bati, a.s.
Oddeleni klinické biochemie
a farmakologie
Prim. MUDr. Tomáš Sálek, Ph.D., EuSpLM
Havlickovo nábřeží 600
76275 ZLIN
CZECH REPUBLIC

Certificate

I. Screening (immunologic)
Correct findings were reported on the following:
- Amphetamine group
- Barbiturates
- Benzodiazepines
- Cannabinoids
- Cocain + metabolites
- Methadon + metabolites
- Opiates
- Tricycl. antidepressants
- Metamphetamin

Bonn, 22. November 2021

C. Knabbe *Dr. J. Geilenkeuser* *A. Kessler*

This certificate is according to the current version of the RiliBÄK valid until the end of May 2022.